Physician profile
John M Peric
NPI 1285664664
$2,600.18
in general payments reported to CMS, 2019-2025
29 companies · $718 in 2025
The $718 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $193 · 2020: $320 · 2021: $353 · 2022: $166 · 2023: $151 · 2024: $700 · 2025: $718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,568.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,568.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $526.94 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $302.37 | 2024-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $219.07 | 2021-2025 | Trelegy Ellipta, Arexvy |
| Phathom Pharmaceuticals, INC. | $206.16 | 2023-2024 | Voquezna |
| Pfizer INC. | $166.26 | 2020-2024 | |
| Gilead Sciences, INC. | $165.72 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $97.41 | 2025 | Rexulti |
| Amgen INC. | $86.91 | 2024-2025 | Repatha, Otezla, Otezla |
| Topcon Healthcare Solutions, INC. | $82.45 | 2019-2020 | |
| Allergan, INC. | $79.33 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $57.09 | 2024-2025 | Zoryve |
| Viiv Healthcare Company | $55.13 | 2024 | Apretude |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.94 | 2025 | Jardiance |
| Almatica Pharma LLC | $50.05 | 2025 | Loreev Xr, Teriparatide |
| Horizon Therapeutics Plc | $46.13 | 2020-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Qol Medical, LLC | $44.02 | 2020 | |
| Upsher-Smith Laboratories LLC | $41.51 | 2020-2021 | |
| Alk-Abello, INC | $40.84 | 2025 | Odactra, Ragwitek, Grastek |
| Dexcom, INC. | $38.18 | 2025 | Dexcom G6 Transmitter |
| Axsome Therapeutics, INC. | $33.59 | 2025 | Auvelity |
| Boston Scientific Corporation | $30.85 | 2022 | |
| Promius Pharma LLC | $28.75 | 2019 | |
| Novo Nordisk INC | $26.03 | 2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $24.22 | 2024 | Zepbound, Mounjaro |
| Spinal Elements, INC. | $23.82 | 2021 | |
| Zyla Life Sciences, INC. | $19.59 | 2019 | |
| Djo, LLC | $19.35 | 2024 | Procare |
| Exact Sciences Corporation | $18.73 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $17.74 | 2023 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Peric listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.